GlassScriptPhysician profile
Margaret Rolfe
NPI 1386340065
$1,476.37
in general payments reported to CMS, 2019-2025
21 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $304 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,476.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $292.66 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $116.38 | 2025 | |
| Phathom Pharmaceuticals, INC. | $113.20 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $110.24 | 2024-2025 | Ozempic, Rybelsus |
| Ardelyx, INC. | $107.28 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $102.31 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.71 | 2024-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $73.44 | 2024-2025 | Breztri, Tezspire |
| Abbvie INC. | $72.58 | 2025 | |
| Pfizer INC. | $72.35 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $64.59 | 2024-2025 | Eliquis |
| Exact Sciences Corporation | $52.27 | 2025 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $35.11 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $27.68 | 2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $24.29 | 2024 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.92 | 2025 | Capvaxive, Gardasil 9 |
| Indivior INC. | $22.71 | 2024 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.64 | 2025 | Relistor |
| Novartis Pharmaceuticals Corporation | $22.57 | 2025 | |
| Lundbeck LLC | $22.33 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $15.11 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Rolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.